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ABSTRACT 
Background: The fatty liver index (FLI) and the hepatic steatosis index (HSI), are biomarker-based 
algorithms developed as proxies for non-alcoholic fatty liver disease (NAFLD). We assessed associations 
of FLI and HSI with cardiovascular disease (CVD) risk.  
Materials and methods: The FLI and HSI were estimated at baseline in the PREVEND cohort involving 
6340 participants aged 28-75 years without pre-existing CVD.  
Results: During a median follow-up of 10.5 years, 631 CVD events occurred. In age- and sex-adjusted 
analysis, the hazard ratio (HR) (95% CI) for CVD comparing FLI ≥ 60 versus FLI < 30 was 1.53 (1.25-
1.88); which was attenuated to 0.89 (0.70-1.13) on adjustment for conventional cardiovascular risk 
factors. The association remained absent after additional adjustment for potential confounders 0.85 (0.65-
1.11). Comparing HSI > 36 versus HSI < 30, the corresponding adjusted HRs were 1.29 (1.02-1.65), 0.84 
(0.65-1.09) and 0.79 (0.55-1.13) respectively. Subgroup analyses suggested a positive association in 
younger participants (< 50 years) for FLI and inverse associations in older participants (≥ 50 years) for 
both indices (P for interaction for all = 0.001).  
Conclusion: Current data suggest age interactions in the association of NAFLD (as assessed by FLI or 
HSI) with CVD risk in a general Caucasian population.  
 
Keywords: Fatty liver index; hepatic steatosis index; non-alcoholic fatty liver disease; cardiovascular 
disease; risk factor 
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1. Introduction 
Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis with varying degrees of 
necroinflammation and fibrosis and which develops in the absence of substantial alcohol intake.[1] First 
described in 1980,[2] it represents a spectrum of liver disease ranging from simple hepatic steatosis to 
nonalcoholic steatohepatitis, fibrosis, and eventually cirrhosis.[1] Nonalcoholic fatty liver disease is now 
more common than alcoholic liver disease and is emerging as the most common cause of chronic liver 
disease in the developed world.[1, 3]  In the absence of the reference standard - liver biopsy - which has 
well-known limitations such as invasiveness and sampling variability,[4] the diagnosis of NAFLD is 
commonly based on (i) imaging techniques [i.e., ultrasonography, computed tomography (CT) scan, or 
magnetic resonance imaging (MRI)] confirming the presence of fat infiltration of the liver and (ii) 
exclusion of other liver diseases of other aetiology.[5] However, these imaging techniques are associated 
with high costs and are not suitable for large-scale population-based epidemiological studies. Elevated 
alanine aminotransferase (ALT) has frequently been used as a biochemical surrogate for NAFLD 
diagnosis, however it is common to diagnose NAFLD in patients with normal ALT levels using 
ultrasonography or histology.[3, 6] A number of biomarker-based indices have been developed to aid the 
diagnosis of fatty liver disease. The fatty liver index (FLI) is based on body mass index (BMI), waist 
circumference (WC), triglycerides (TGs), and gamma-glutamyltransferase (GGT).[7] The hepatic 
steatosis index (HSI) is also a simple algorithm that is based on three variables [Alanine 
aminotransferase/aspartate aminotransferase ratio, BMI, and diabetes].[8] Both indices have been 
reported to have good diagnostic accuracies.[7-9]   
Nonalcoholic fatty liver disease is associated with an increased risk of mortality, with CVD being the 
most common cause among NAFLD patients.[10, 11] There is a rapidly growing body of evidence that 
supports the existence of a strong link between NAFLD and risk of CVD. During the past few decades, a 
number of prospective studies have reported on the associations between NAFLD and cardiovascular risk 
[10-16] However, the variability in study designs, small sample sizes, short follow-up durations, 
insufficient adjustment for established cardiovascular risk factors, and inconsistent results, limit the 
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validity and generalisation of these findings. Whilst some studies used retrospective cohort designs with 
small patient populations;[10, 11, 15, 17] other studies were conducted in selected populations such as 
participants with pre-existing type 2 diabetes or vascular disease;[12, 13, 18] or studies used elevated 
liver enzyme levels as surrogate markers of NAFLD.[19] Some studies observed associations of NAFLD 
with risk of CVD,[14] and others showed no associations at all,[11, 15, 16] leaving great uncertainty 
regarding the nature of the association. Reviews of the literature have also reached conflicting 
conclusions.[20, 21] Evaluation of this association is important, because NAFLD is a global public health 
burden and an emerging risk factor for CVD.  
Our aim was to assess the prospective association of NAFLD (as estimated by these two indices - FLI 
and HSI) with risk of CVD, using a large population-based sample of 6340 participants free from pre-
existing CVD at baseline.  
 
2. Materials and methods 
2.1. Study design and participants  
This report was conducted according to STROBE (STrengthening the Reporting of OBservational 
studies in Epidemiology) guidelines for reporting observational studies in epidemiology (Supplementary 
material 1).[22]  
The study population comprised a representative sample of inhabitants aged 28-75 years living in the city 
of Groningen, the Netherlands, who were recruited into the Prevention of Renal and Vascular End-stage 
Disease (PREVEND) prospective cohort study; which was designed to investigate the natural course of 
urinary albumin excretion and its relation to renal and cardiovascular disease. Details of the study design 
and recruitment of participants have been described in detail elsewhere.[23, 24] In brief, of all inhabitants 
invited for pre-screening, 40,856 responded. After exclusion of patients with type 1 diabetes mellitus and 
pregnant females, 11,162 subjects were deemed eligible. Of these, 8,592 participated (77% participation 
rate) and constituted the actual PREVEND cohort. Baseline measurements were performed between 1997 
and 1998. Participants with a prevalent history of CVD, renal disease, or malignancy were excluded in the 
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present analysis. We also excluded participants with excessive alcohol use (defined as four or more drinks 
per day) and those on medication for treating hyperlipidemia, which left a final cohort of 6340 subjects 
with non-missing information on relevant components for the two exposures, CVD risk markers, and 
outcomes for the present analysis. The derivation of the analytic sample is reported in Supplementary 
material 2. The medical ethics committee of the University Medical Center Groningen duly approved the 
PREVEND study, which complies with the Declaration of Helsinki. Each participant provided written 
informed consent for voluntary participation, which was documented in a consent form. 
 
2.2. Risk factor assessment 
Plasma glucose measurements were made using dry chemistry (Eastman Kodak, Rochester, New 
York). Blood lipid [total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglycerides], 
high sensitivity C-reactive protein (hsCRP), serum creatinine, and serum cystatin C were measured using 
standard laboratory methods, which have been described in previous reports. High-density lipoprotein 
cholesterol was measured with a homogeneous method (direct HDL, AEROSETTM System, Abbott 
Laboratories, Abbott Park, USA).[25] Triglycerides were measured enzymatically. Total cholesterol and 
plasma glucose were assessed using Kodak Ektachem dry chemistry (Eastman Kodak, Rochester, New 
York, USA). Urinary albumin excretion (UAE) was calculated as the mean of two 24-hour urine 
collections. Serum liver aminotransferase activities were measured using the standardized kinetic method 
with pyridoxal phosphate activation (Roche Modular P; Roche Diagnostics, Mannheim, Germany) 
according to the recommendations of the International Federation of Clinical Chemistry.[26, 27] Serum 
GGT activity was measured by an enzymatic colorimetric method (Roche Modular P; Roche Diagnostics, 
Mannheim, Germany). Total bilirubin was measured by a colorimetric assay (2,4-dicholoraniline reaction; 
Merck MEGA, Darmstadt, Germany). Diabetes was defined as a fasting glucose level of ≥ 7.0 mmol/L, a 
nonfasting glucose level of ≥ 11.1 mmol/L and/or use of glucose lowering medication according to 
self‐report or to pharmacy data.[28]  
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2.3. Measures of NAFLD 
The FLI was calculated based on the report by Bedogni and colleagues [7] using the following 
formula: 
FLI = [e(0.953 x ln(TG) + 0.139 x BMI + 0.718 x ln(GGT) + 0.053 x WC - 15.745)] / [1 + e(0.953 x ln(TG) + 0.139 x BMI + 0.718 x ln(GGT) + 0.053 x 
WC - 15.745)] x 100 
The FLI ranges from 0 to 100, with FLI < 30 ruling out (sensitivity = 87%) and FLI ≥ 60 ruling in fatty 
liver disease (specificity = 86%) with a good diagnostic accuracy of 0.84 (95% CI: 0.81-0.87). 
The HSI was estimated using the following formula as reported by Lee and colleagues:[8] 
HSI = 8 x ALT/AST ratio + BMI (+2, if diabetes; +2, if female); with HSI values < 30 and > 36 ruling 
out and ruling in fatty liver respectively and has a diagnostic accuracy of 93.1%. 
 
2.4. Endpoint ascertainment 
We included all first-onset composite CVD events that occurred from study enrollment through to 01-
01-2011. Information on the dates and causes of death were ascertained by record linkage with the Dutch 
Central Bureau of Statistics, whiles information on hospitalization for cardiovascular morbidity was 
received from PRISMANT; which is the Dutch national registry of hospital discharge diagnoses. The 
validity of information from this database has been shown to be reliable, with 84% of primary diagnoses 
and 87% of secondary diagnoses matching the diagnoses recorded in patients’ charts.[29] Outcomes were 
coded according to the International Classification of Diseases, Ninth Revision (ICD-9) until 01-01-
2009. After this date, ICD-10 codes were employed. First-onset CVD was defined as the combined 
endpoint of acute myocardial infarction, acute and subacute ischemic heart disease, coronary artery 
bypass grafting or percutaneous transluminal coronary angioplasty, subarachnoid hemorrhage, 
intracerebral hemorrhage, other intracranial hemorrhage, occlusion or stenosis of the precerebral or 
cerebral arteries, and other vascular interventions such as percutaneous transluminal angioplasty or 
bypass grafting of peripheral vessels and aorta. 
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2.5. Statistical analysis 
The analyses were pre-specified to exclude participants with a history of CVD at baseline. Skewed 
variables such as ALT, AST, triglycerides, hsCRP, creatinine, UAE, and total bilirubin were natural log-
transformed to approximate normal distributions. Descriptive analyses were performed to summarize 
baseline characteristics of participants according to categories of the FLI and HSI. Associations of FLI 
and HSI with CVD risk were evaluated using Cox regression hazards models, after confirmation of 
assumptions of proportionality of hazards. Hazard ratios were progressively adjusted for age and sex; 
other established CVD risk factors [age, sex, smoking status, history of diabetes, systolic blood pressure 
(SBP), total cholesterol, and HDL-C]; potential confounders such as alcohol consumption, glucose, and 
UAE; and further for  triglycerides (for HSI), total bilirubin, hsCRP, and the homeostasis model 
assessment-estimated insulin resistance (HOMA-IR). We performed subgroup analyses using interaction 
tests to assess statistical evidence of any differences in HRs across categories of pre-specified individual 
characteristics [such as age, sex, smoking status, alcohol consumption, history of diabetes, BMI (obese 
versus non-obese), history of hypertension, total cholesterol (hypercholesterolemia versus non-
hypercholesterolemia), HDL-C (low to average versus optimal levels), hsCRP (low to average versus 
high cardiovascular risk[30]), UAE, and total bilirubin]. All  s tatistical analyses were conducted using 
Stata version 14 (Stata Corp, College Station, Texas) and 2-sided P-values < 0.05 were considered 
statistically significant.  
 
3. Results 
3.1. Baseline characteristics  
Overall, the mean age at baseline of the 6340 participants eligible for the present study was 48 (SD 12) 
years and 54% were women. During a median (interquartile range) follow-up of 10.5 (9.6-10.8) years, 
631 incident CVD events were recorded. Baseline descriptive characteristics of the participants according 
to categories of the FLI and HSI are shown in Tables 1 and 2. Individuals in the higher FLI categories 
were older, more likely to have diabetes, and generally had adverse levels of cardiometabolic parameters 
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(anthropometric indices, blood pressure, lipids, fasting glucose, hsCRP, and renal function markers) 
compared to the lowest category of FLI (< 30). A similar pattern was observed for categories of the HSI. 
Figure 1 shows proportions of participants who developed incident CVD in the categories of FLI and 
HSI. 
 
3.2. FLI and risk of incident CVD 
In age- and sex-adjusted analysis, compared to the reference category of FLI (< 30), the HR for CVD 
for individuals in the top FLI category (≥ 60) was 1.53 (95% CI: 1.25 to 1.88; P<0.001). The 
corresponding HR was attenuated to 0.89 (95% CI: 0.70 to 1.13; P=0.354) after additional adjustment for 
smoking status, history of diabetes, SBP, total cholesterol, and HDL-C, and this remained consistent on 
further adjustment for alcohol consumption, fasting glucose, and UAE; as well as total bilirubin, hsCRP, 
and HOMA-IR (Table 3). The HRs generally did not vary significantly by levels or categories of several 
clinically relevant characteristics, except for a highly significant interaction by age (P for interaction = 
0.001). Remarkably, a positive association was in younger individuals (< 50 years) compared with an 
inverse association in older individuals (≥ 50 years) (Figure 2). To evaluate if the age interaction on the 
association could be due to reverse causation, we carried out subsidiary analysis that excluded first two 
years of follow-up. The findings still showed significant evidence of an age interaction; a positive 
association was observed in younger individuals 1.67 (95% CI: 1.07 to 2.61; P=0.024) compared to a less 
robust inverse association in older individuals 0.81 (95% CI: 0.60 to 1.08; P=0.156) (P for interaction = 
0.006). 
 
3.3. HSI and risk of incident CVD  
Compared to the reference category of HSI (< 30), the HR for CVD for individuals in the top HSI 
category (> 36) was 1.29 (95% CI: 1.02 to 1.65; P=0.035) in age- and sex-adjusted analysis. In additional 
adjustment for smoking status, history of diabetes, SBP, total cholesterol, and HDL-C, the corresponding 
HR was attenuated to 0.84 (95% CI: 0.65 to 1.09; P=0.180) and this remained persistent on further 
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adjustment for potential confounders (Table 4). In subgroup analyses, there were significant interactions 
by age (P for interaction = 0.001), smoking status (P for interaction = 0.008), and hsCRP (P for 
interaction = 0.05). Inverse associations were seen for older individuals (≥ 50 years), current and former 
smokers, and individuals with hsCRP > 3.0 mg/l (Figure 1). In subsidiary analyses that excluded first two 
years of follow-up, subgroup analysis still showed evidence of an inverse association among older 
individuals 0.69 (95% CI: 0.49 to 0.97; P=0.032) (P for interaction = 0.003). 
 
4. Discussion 
4.1. Key findings 
In this large-scale population-based study of individuals without a history of CVD at baseline, we 
observed no association between NAFLD (as assessed by FLI and HSI) and the risk of CVD in analyses 
adjusted for established risk factors and further for potential confounders and mediators. The null 
associations remained generally consistent across several clinically relevant subgroups, except for 
significant interactions by age, blood pressure, smoking status, renal function, and hsCRP. Using FLI as 
an index of NAFLD, an inverse association was seen in older individuals compared to a positive 
association in younger individuals. A similar pattern of effect modification by age was also observed 
when HSI was used as a proxy for NAFLD. Different and even opposing associations were also seen for 
smokers versus non-smokers.  
 
4.2. Comparison with previous work 
A number of previous studies have assessed the association of FLI with the risk of incident type 2 
diabetes and have demonstrated strong positive associations.[9, 31] Yadav and colleagues have also 
recently shown that the FLI significantly improves diabetes risk prediction.[32] We are however unable to 
directly compare the current findings with previous work, as no prospective study to date has evaluated 
the association of the FLI or the HSI with the risk of CVD. The current results seem to be in contrast with 
those of prospective cohort studies that have reported on NAFLD (as diagnosed by imaging or histology) 
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and the risk of CVD. However, given the limitations of some of these previous study designs, the 
inconsistent evidence, and controversy surrounding the relationship between NAFLD and CVD, this may 
probably not be the case. Targher and colleagues using a prospective outpatient cohort showed NAFLD 
(diagnosed by ultrasonography) to be independently associated with fatal and non-fatal CVD events; 
however the cohort comprised selected patients with type 2 diabetes.[13] In a prospective cohort of 
apparently healthy Japanese men and women, NAFLD as diagnosed using ultrasonography, was 
demonstrated to be independently associated with risk of CVD; however, a main limitation of this study 
was that the incidence of CVD was assessed by self-administered questionnaires.[14] Pisto and colleagues 
using a Finnish cohort comprising mainly patients with established hypertension, showed NAFLD to be 
associated with fatal and non-fatal CVD in unadjusted analysis.[33] The results of Zeb and colleagues 
using the Multi-Ethnic Study of Atherosclerosis, suggested NAFLD (as diagnosed using non-enhanced 
CT scan) to be independently associated with risk of CVD; however, a composite endpoint of nonfatal 
coronary disease and all-cause mortality events was used.[34]  
 
4.3. Possible explanations for findings 
In line with established evidence which shows that NAFLD is associated with an increased risk of type 
2 diabetes; accruing evidence suggests that NAFLD may also be involved in the pathogenesis of CVD. 
The putative underlying mechanisms linking increased cardiovascular risk with NAFLD is believed to 
originate from the expanded and inflamed visceral adipose tissue. The liver in its necroinflammatory form 
- non-alcoholic steatohepatitis – releases a vast array of pro-atherogenic and pro-inflammatory factors 
which are potentially involved in the development of insulin resistance and atherogenic dyslipidemia.[21, 
35, 36] Insulin resistance is a pathogenic factor which plays a major role in the development of both the 
metabolic syndrome and CVD.[37] Nonalcoholic fatty liver disease is also associated with decreased 
plasma levels of adiponectin,[38] an adipose-secreted cytokine with anti-atherogenic properties and which 
has been shown to independently predict CVD.[39] However, despite the emerging evidence implicating 
a potential pathogenic role of NAFLD in the development of CVD; prospective observational cohorts 
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have been unable to consistently demonstrate a robust and independent association. Given the limited 
study designs of previous studies that have reported positive associations, there is a possibility that these 
associations demonstrated could be due to the effects of selection bias, reverse causation, and/or residual 
confounding. Nonetheless, the current results also bring into question the reliability of the FLI and HSI as 
suitable proxies for NAFLD. In the absence of liver biopsy, which is the gold standard for the diagnosis 
of fatty liver disease, these two scoring systems - which employ easy-to-measure variables – have been 
shown to detect fatty liver disease with considerable accuracy in comparison with ultrasonography.[7, 8] 
In addition, these indices have been externally validated in several populations and shown to have 
moderate diagnostic accuracy for steatosis in these populations.[40, 41] However, the FLI and HSI cannot 
substitute liver biopsy or MRI [41, 42] and only serve as surrogate measures of NAFLD. Overall, the 
evidence base for the association between NAFLD and CVD risk is still weak and further investigation is 
required. In our findings, we observed evidence of effect modification by a number of clinically relevant 
baseline characteristics; of which the most striking was age. Given the low event rate in some of the 
subgroups and the multiple statistical tests for interaction conducted, some of these observations should 
be interpreted with caution and require replication in further studies. For age, a consistent inverse 
association was seen in older individuals for both indices, whiles a positive association was observed in 
younger individuals for FLI. The age differences in the associations remained consistent in sensitivity 
analyses that excluded the first two years of follow-up and adjusted for other potential confounders. There 
is a possibility that the age interactions in the associations (inverse associations in participants who were 
≥ 50 years) might due to the effect of exclusion at baseline of participants with prevalent history of CVD, 
renal disease, malignancy, and lipid medication; who were older and were more likely to have NAFLD. 
The findings might also reflect emerging evidence that ALT (commonly used as a surrogate measure of 
NAFLD) is an indicator of aging, sarcopenia, and frailty,[43, 44] which are associated with an increased 
risk of CVD.[45] Age has been suggested to play a role in mediating the association between ALT and 
CVD.[46] Indeed, we and others have shown that age modifies the relationship between ALT and CVD 
risk.[44, 46] Our findings may also reflect the paradoxical relationships between the aminotransferases, 
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diabetes, and CVD; which we and others have previously reported.[46, 47] These theories are biologically 
plausible but are speculative and therefore further research is needed to clarify these mechanistic 
pathways. 
 
4.4. Study strengths and limitations 
Several strengths of the current study merit consideration. To our knowledge, this is the first 
comprehensive epidemiological investigation of the prospective association between CVD risk and 
NAFLD using two validated indices. Our analyses was based on large-scale epidemiological data 
comprising of participants representative of the general population with over a decade of follow-up and 
usage of validated CVD events. To minimize possibilities of reverse-causation bias, this current study was 
designed to involve individuals free of clinically evident prior vascular disease or other chronic disorders 
at baseline. Potential bias due to reverse causation which could have been responsible for the age 
differences in the associations was minimised by excluding the first two years of follow-up in sensitivity 
analysis. We had measurements of several lifestyle and biological markers which enabled comprehensive 
adjustment for potential confounding. Limitations of the current analyses include (i) the potential residual 
confounding due to unmeasured confounders and errors in measurements of potential confounders; (ii) 
inability to differentiate between alcoholic fatty liver disease and NAFLD with certainty; though we 
excluded subjects with excessive alcohol consumption; and (iii) our definition of excessive alcohol 
consumption was based on number of drinks per day (four or more drinks per day) which may be an 
approximation, as we did not have complete data on the specific amount of alcohol consumed by study 
participants.  
In conclusion, available data suggest that there are age interactions in the association of NAFLD (as 
assessed by FLI or HSI) with the risk of CVD in a general Caucasian population. Further study is required 
to replicate these findings and understand the mechanisms responsible for the age differences in the 
associations. 
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Table 1 Baseline participant characteristics according to categories of the fatty liver index (FLI) 
 < 30 
(N=3,298) 
Mean (SD) or 
median (IQR) or n 
(%) 
 
30 to < 60 
(N=1,500) 
Mean (SD) or 
median (IQR) or n 
(%) 
 
≥ 60 
(N=1,542) 
Mean (SD) or 
median (IQR) or n 
(%) 
 
P-value 
     
Questionnaire     
Male 1,035 (31.4) 891 (59.4) 1,017 (66.0) < 0.001 
Age at survey (years) 43.9 (11.2) 51.5 (12.9) 53.2 (11.6) < 0.001 
History of diabetes 16 (0.5) 43 (2.9) 118 (7.7) < 0.001 
Smoking     
    Current 1,094 (33.1) 456 (30.4) 503 (32.6) < 0.001 
    Former 1,034 (31.4) 602 (40.1) 634 (41.1) - 
    Never 1,170 (35.5) 442 (29.5) 405 (26.3) - 
Moderate drinkers 2,523 (76.5) 1,108 (73.9) 1,084 (70.3) < 0.001 
History of hypertension 119 (3.6) 168 (11.2) 292 (18.9) < 0.001 
Regular use of anti-hypertensive 
medication 
153 (4.6) 187 (12.5) 296 (19.2) < 0.001 
     
Physical measurements     
BMI (kg/m2) 23.3 (2.4) 26.8 (2.4) 30.7 (4.1) < 0.001 
WHR 0.82 (0.07) 0.90 (0.07) 0.96 (0.08) < 0.001 
WC 78.2 (7.8) 91.6 (6.3) 102.9 (9.2) < 0.001 
SBP (mmHg) 120 (17) 132 (19) 140 (19) < 0.001 
DBP (mmHg) 70 (9) 75 (9) 79 (9) < 0.001 
     
Lipid markers     
Total cholesterol (mmol/l) 5.24 (1.02) 5.87 (1.09) 6.14 (1.08) < 0.001 
HDL-C (mmol/l) 1.51 (0.40) 1.23 (0.32) 1.08 (0.29) < 0.001 
Triglycerides (mmol/l) 0.88 (0.68-1.12) 1.28 (1.00-1.70) 1.89 (1.37-2.69) < 0.001 
     
Metabolic,  inflammatory, liver, 
and renal function markers 
    
hsCRP (mg/l) 0.72 (0.34-1.75) 1.49 (0.73-3.13) 2.31 (1.15-4.79) < 0.001 
Fasting plasma glucose (mmol/l) 4.47 (0.57) 4.90 (1.04) 5.35 (1.57) < 0.001 
Creatinine (µmol/l) 78 (71-86) 85 (76-94) 87 (77-96) < 0.001 
Cystatin C (mg/dl) 0.75 (0.18) 0.82 (0.22) 0.84 (0.18) < 0.001 
UAE (mg/24 hours) 7.90 (5.78-12.29) 9.38 (6.41-16.85) 13.21 (7.87-29.45) < 0.001 
Total bilirubin (µmol/l) 7 (5-9) 7 (5-9) 6 (5-9) < 0.001 
 
BMI, body mass index; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; ; hsCRP, high sensitivity C-reactive protein; 
IQR, interquartile range; SBP, systolic blood pressure; UAE, urinary albumin excretion; WC, waist circumference; WHR, waist-to-hip ratio 
 
20 
 
Table 2 Baseline participant characteristics according to categories of the hepatic steatosis index (HSI)  
 < 30 
(N=1,460) 
Mean (SD) or 
median (IQR) or n 
(%) 
 
30 to ≤ 36 
(N=2,897) 
Mean (SD) or 
median (IQR) or n 
(%) 
 
> 36 
(N=1,983) 
Mean (SD) or 
median (IQR) or n 
(%) 
 
P-value 
     
Questionnaire     
Male 652 (44.7) 1,317 (45.5) 974 (49.1) 0.013 
Age at survey (years) 43.2 (11.4) 48.4 (12.6) 50.9 (11.9) < 0.001 
History of diabetes 4 (0.3) 43 (1.5) 130 (6.6) < 0.001 
Smoking     
    Current 582 (39.9) 919 (31.7) 552 (27.8) < 0.001 
    Former 400 (27.4) 1,076 (37.1) 794 (40.0) - 
    Never 478 (32.7) 902 (31.1) 637 (32.1) - 
Moderate drinkers 1,144 (78.4) 2,213 (76.4) 1,358 (68.5) < 0.001 
History of hypertension 39 (2.7) 226 (7.8) 314 (15.8) < 0.001 
Regular use of anti-hypertensive 
medication 
55 (3.8) 244 (8.4) 337 (17.0) < 0.001 
     
Physical measurements     
BMI (kg/m2) 21.5 (1.7) 25.1 (2.0) 30.3 (3.9) < 0.001 
WHR 0.82 (0.08) 0.86 (0.09) 0.92 (0.09) < 0.001 
WC 76.1 (8.4) 85.5 (9.6) 98.6 (11.2) < 0.001 
SBP (mmHg) 118 (16) 127 (20) 135 (19) < 0.001 
DBP (mmHg) 69 (9) 73 (10) 77 (9) < 0.001 
     
Lipid markers     
Total cholesterol (mmol/l) 5.18 (1.01) 5.60 (1.12) 5.93 (1.10) < 0.001 
HDL-C (mmol/l) 1.50 (0.41) 1.37 (0.39) 1.18 (0.34) < 0.001 
Triglycerides (mmol/l) 0.89 (0.69-1.18) 1.08 (0.81-1.52) 1.46 (1.05-2.15) < 0.001 
     
Metabolic,  inflammatory, liver, 
and renal function markers 
    
hsCRP (mg/l) 0.60 (0.28-1.54) 1.07 (0.50-2.37) 2.04 (0.99-4.29) < 0.001 
Fasting plasma glucose (mmol/l) 4.42 (0.61) 4.69 (0.81) 5.20 (1.48) < 0.001 
Creatinine (µmol/l) 79 (72-88) 82 (73-91) 84 (74-93) < 0.001 
Cystatine C (mg/dl) 0.75 (0.18) 0.79 (0.20) 0.81 (0.19) < 0.001 
UAE (mg/24 hours) 8.03 (5.87-12.94) 8.77 (6.08-14.62) 10.68 (6.85-21.46) < 0.001 
Total bilirubin (µmol/l) 7 (6-10) 7 (5-9) 6 (5-8) < 0.001 
 
BMI, body mass index; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; ; hsCRP, high sensitivity C-reactive protein; 
IQR, interquartile range; SBP, systolic blood pressure; UAE, urinary albumin excretion; WC, waist circumference; WHR, waist-to-hip ratio 
 
 
 
Table 3 Association of fatty liver index (FLI) with cardiovascular disease 
FLI categories Events/ 
Total 
Model 1  Model 2  Model 3  Model 4  
  HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
< 30 174 / 3,298 ref  ref  ref  ref  
30 to < 60 187 / 1,500 1.12 (0.90 to 1.40) 0.290 0.84 (0.67 to 1.06) 0.145 0.85 (0.67 to 1.07) 0.164 0.82 (0.65 to 1.04) 0.102 
≥ 60 270 / 1,542 1.53 (1.25 to 1.88) < 0.001 0.89 (0.70 to 1.13) 0.354 0.86 (0.68 to 1.10) 0.234 0.85 (0.65 to 1.11) 0.226 
 
CI, confidence interval; HR, hazard ratio 
Model 1: Age and sex 
Model 2: Model 1 plus smoking status, history of diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein-cholesterol 
Model 3: Model 2 plus alcohol consumption, glucose, and loge urinary albumin excretion 
Model 4: Model 3 plus loge total bilirubin, loge high sensitivity C-reactive protein, and loge homeostasis model assessment-estimated insulin resistance 
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Table 4 Association of hepatic steatosis index (HSI) with cardiovascular disease 
HSI categories Events/ 
Total 
Model 1  Model 2  Model 3  Model 4  
  HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
< 30 93 / 1,460 ref  ref  ref  ref  
30 to ≤ 36 279 / 2,897 1.04 (0.82 to 1.31) 0.770 0.83 (0.65 to 1.06) 0.127 0.79 (0.61 to 1.04) 0.090 0.83 (0.64 to 1.08) 0.172 
> 36 259 / 1,983 1.29 (1.02 to 1.65) 0.035 0.84 (0.65 to 1.09) 0.180 0.73 (0.51 to 1.05) 0.090 0.79 (0.55 to 1.13) 0.204 
 
CI, confidence interval; HR, hazard ratio 
Model 1: Age and sex 
Model 2: Model 1 plus smoking status, systolic blood pressure, total cholesterol, and high-density lipoprotein-cholesterol 
Model 3: Model 2 plus alcohol consumption, glucose, and loge urinary albumin excretion 
Model 4: Model 3 plus loge triglycerides, loge total bilirubin, loge high sensitivity C-reactive protein, and loge homeostasis model assessment-estimated insulin resistance 
 
  
Figure 1. Proportions on incident cardiovascular disease cases by categories of FLI and HSI 
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CVD, cardiovascular disease; FLI, fatty liver index; HR, hazard ratio; HSI, hepatic steatosis index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Hazard ratios for FLI, HSI, and cardiovascular disease risk by several participant level characteristics 
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Hazard ratios were adjusted for age, sex, smoking status, history of diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein 
cholesterol (HDL-C); CI, confidence interval (bars); hsCRP, high sensitivity C-reactive protein; FLI, fatty liver index; HR, hazard ratio; HSI, 
hepatic steatosis index; UAE, urinary albumin excretion; *, P-value for interaction; cut-offs used for total bilirubin are median values. 
 
 
